BlueChew Review
Advertising Disclosure: TelehealthIndex is reader-supported. If you sign up with a
provider through links on this page, we may earn a commission at no extra cost to you.
Commissions never influence our scores or rankings — several of our top-rated providers pay
us nothing. How we score → · Full disclosure →
Caution: unresolved FDA warning letter. This provider stays at its computed rank; its score is capped under
our methodology and it is not recommended while the matter is open.
42.4/100
BlueChew score
Not Recommended · #10 in Men's Health (ED & TRT) · Data as of July 2026 · No affiliate relationship
Clinical credibilityWeak
Regulatory & safety recordSerious deductions
Transparency & trustMixed
Access & coverageLimited
Customer experienceMixed
Value & pricingGood
Pillar ratings are qualitative summaries of our internal rubric; we do not publish the
point weights. Read the full methodology →
TelehealthIndex scores and rankings are editorial opinions resulting from our selection, weighting, and interpretation of the factors described in our methodology.
What it is
ED-only pure play; entire product line is compounded chewables (not FDA-approved); received Sept 2025 FDA warning letter.
Strengths
- Available in 49 states
- Lower-cost pricing for the category
Considerations
- CONFIRMED FDA warning letter Sept 2025 (Viagra/Cialis equivalence claims on compounded chewables) - Caution gate applies
- BBB accreditation suspended; free-trial/cancellation criticism (TINA.org)
Note: this provider offers compounded medications for one or more services.
Compounded medications are not FDA-approved.
Founded2017
OwnershipPrivate (self-funded)
Availability49 states
InsuranceNo
Money-back guaranteeNot advertised
Pricing$25-130/mo (~$3.80-6.25 per chew); free consult
Visit BlueChew
We may earn a commission — disclosure.
Alternatives to consider
Sources
Every regulatory claim on this page is cited to its primary source (or the issuing agency's database). Verified against the cited document; see our Editorial Policy.
Data as of July 19, 2026. Scores are editorial opinions reflecting documented business practices, transparency, pricing, access, and nonclinical consumer-service factors — not clinical quality or outcomes. Found an error? Report it →